Shenzhen New Industries Biomedical Engineering Co., Ltd. (SHE:300832)
China · Delayed Price · Currency is CNY 46.89
-1.06 (-2.21%)
Aug 4, 2026, 3:04 PM CST
SHE:300832 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 37,675 | 44,197 | 55,668 | 61,443 | 39,416 | 34,652 | |
Market Cap Growth | -11.61% | -20.61% | -9.40% | 55.88% | 13.75% | -36.36% |
Enterprise Value | 35,256 | 41,941 | 53,087 | 58,196 | 36,450 | 31,451 |
Last Close Price | 47.95 | 54.84 | 67.53 | 73.57 | 46.60 | 40.36 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 23.19 | 27.28 | 30.45 | 37.16 | 29.68 | 35.59 |
Forward PE | 20.41 | 24.30 | 25.23 | 31.02 | 27.83 | 28.70 |
PS Ratio | 8.22 | 9.66 | 12.27 | 15.64 | 12.94 | 13.61 |
PB Ratio | 3.97 | 4.83 | 6.49 | 8.14 | 6.16 | 6.18 |
P/TBV Ratio | 4.07 | 4.96 | 6.68 | 8.33 | 6.33 | 6.28 |
P/FCF Ratio | 24.79 | 36.50 | 60.69 | 56.06 | 70.49 | 80.54 |
P/OCF Ratio | 20.22 | 29.03 | 41.04 | 43.32 | 40.96 | 44.82 |
PEG Ratio | 1.40 | 3.05 | 1.21 | 1.21 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 7.70 | 9.16 | 11.71 | 14.81 | 11.96 | 12.36 |
EV/EBITDA Ratio | 17.48 | 21.35 | 25.12 | 30.82 | 25.23 | 27.32 |
EV/EBIT Ratio | 19.39 | 23.66 | 27.47 | 33.48 | 27.35 | 29.74 |
EV/FCF Ratio | 23.19 | 34.63 | 57.88 | 53.09 | 65.19 | 73.10 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0 | 0 | 0 | 0.00 | 0 | 0 |
Debt / EBITDA Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Debt / FCF Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 |
Net Debt / Equity Ratio | -0.25 | -0.37 | -0.32 | -0.45 | -0.53 | -0.61 |
Net Debt / EBITDA Ratio | -1.20 | -1.72 | -1.28 | -1.80 | -2.36 | -2.97 |
Net Debt / FCF Ratio | -1.59 | -2.80 | -2.96 | -3.10 | -6.09 | -7.95 |
Asset Turnover | 0.46 | 0.47 | 0.51 | 0.52 | 0.46 | 0.45 |
Inventory Turnover | 1.23 | 1.26 | 1.20 | 1.21 | 1.22 | 1.33 |
Quick Ratio | 6.06 | 7.31 | 4.21 | 6.96 | 6.73 | 7.31 |
Current Ratio | 10.54 | 8.98 | 5.56 | 8.56 | 8.26 | 8.85 |
Return on Equity (ROE) | 17.57% | 18.29% | 22.68% | 23.72% | 22.11% | 18.70% |
Return on Assets (ROA) | 11.39% | 11.33% | 13.54% | 14.26% | 12.67% | 11.55% |
Return on Invested Capital (ROIC) | 24.66% | 26.65% | 33.73% | 42.54% | 45.48% | 50.11% |
Return on Capital Employed (ROCE) | 18.80% | 19.10% | 22.20% | 22.80% | 20.70% | 18.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 4.31% | 3.67% | 3.28% | 2.69% | 3.37% | 2.81% |
FCF Yield | 4.03% | 2.74% | 1.65% | 1.78% | 1.42% | 1.24% |
Dividend Yield | 2.51% | 2.19% | 1.93% | 1.36% | 1.50% | 1.49% |
Payout Ratio | 62.89% | 63.07% | 42.98% | 33.15% | 35.53% | 42.46% |
Buyback Yield / Dilution | 0.00% | -0.00% | 0.01% | 0.07% | -0.04% | -4.76% |
Total Shareholder Return | 2.51% | 2.19% | 1.94% | 1.42% | 1.46% | -3.27% |